FCGR3A and melanoma: Serum from pembrolizumab treated melanoma patients with elevated AHA were therefore tested for their ability to induce downregulation of CD16 and cytotoxic activity in the presence of pembrolizumab- F(ab’)2 (Fig 5B and 5D).